Does big data really make health care better?

After decades of technological development in the pharmaceutical industry, it is now in its big data age. The development of mobile technology, sensors, genome analysis and analysis software has made it possible to capture a large amount of personal information, including the body's composition and surroundings, which have changed the pharmaceutical industry. Industry goals from the popular treatment into personalized diagnosis and treatment, the control of the increase, which for doctors and patients is undoubtedly a good news.

Business opportunities hidden in these medical data could be as high as $3000.45 trillion a year, according to McKinsey, a consultancy.

McKinsey consultants have suggested that Apple, Qualcomm and IBM invest in the technology industry, small to smartphone apps, to an analysis system worth 1 billion of billions of dollars. And some small companies have just started to drool. According to Markham Capital Group, the pharmaceutical industry has entered an unprecedented period of rapid development since 2013, and some venture capital companies, such as Greloc Partnership, Kleiner, and some companies such as Google, Samsung and Merck, have injected more than 3 billion of billions of dollars in venture capital into medical information technology.

However, we have to ask, does big data really make health care better?

"The data we're collecting is far from enough, and what we really need to do is find ways to make the data work," says Edmartin, a temporary director for the Information Services department at the San Francisco Medical School in California. ”

"We are willing to believe that everything we do about medicine is justified, but that's not the case," said Malaygandhi, Rockhealth's general manager, Rockhealth, a start-up incubator focused on mobile medicine. A large part lacks scientific factual evidence. Therefore, the medical data with scientific basis and science analysis is the correct development direction of the future market. ”

A business report in the MIT Tech Review (Mittechnologyreview) argues that these technologies and companies are likely to be just a moment of prosperity, and are facing a huge challenge to push the medical cause to another peak.

In any case, the change has taken place, looking forward to a better future

The largest number of medical data is currently controlled by insurers and other health-care providers, whose data analysis has begun to change the health care industry. Isairip, the American pharmacy management company, has nearly 90 million of the annual pharmacy receipts and 1.4 billion of dollars in drug profits, analyzing large amounts of data from hospitals, pharmacies and laboratories, and warning doctors of potential adverse drug cross reactions and other drug use considerations. Doctors can predict in advance whether their patients are effective in using these drugs, with an accuracy of up to 98%. As a result, they can avoid treatment failures and, from another perspective, reduce US $317 billion trillion in annual U.S. medical malpractice.

The big data also changed the patient's role in treatment, not blindly accepting it, but dominating his health. One example is the use of mobile technology to detect their sleep patterns, heart rate, motor level and so on. In addition, a number of more advanced devices are also being developed rapidly, such as real-time monitoring of human body index devices, including blood oxygen concentrations, glucose levels, and even stress. Companies like Apple even want to collect the data in order to provide consumers with a variety of new ways to monitor and improve their physique.

Such information is interesting and valuable to anyone, and is important for thousands of chronically ill people (such as diabetes, heart disease, depression). WellDoc, a mobile medical company focused on diabetes management, has developed a mobile phone program that patients can treat for themselves, and the FDA's only approved patient guidance system, which combines software to monitor blood sugar levels, recent diets, Exercise and other information to provide patients with an optimal insulin intake. A notable feature of this is its ability to predict low blood sugar levels and to help patients avoid hypoglycemia.

Ferenmeck de Mide (phelan-mcdermid) syndrome is a rare chromosome 22nd deficiency syndrome that results in loss of learning and memory, and these patients are creating a large database containing genomic information, clinical drug records, patient family surveys, and other historical data. The researchers want to build a database storage center to simultaneously analyze and detect data from different sources. This creative inspiration stems from the researchers ' findings that there is a certain correlation between Macdemide syndrome, autism and other diseases. Another goal is to focus data on a particular academic research laboratory, which greatly facilitates the process of obtaining information from experts and scholars in different regions.

The daughter of the

Megano ' Boyle, Shannon, who was diagnosed with the Roentgen Macdemide syndrome in 2001, carried out a sequencing of chromosome 22nd 2 years later, saying: "All the relevant data are ready and are now being used for treatment." The